Flu vaccine strain selection
Influenza virus strains to be included in the vaccine for the 2005-2006 season will be reviewed by FDA's Vaccines & Related Biological Products Advisory Committee Feb. 16. Committee will hear updates on FDA's Critical Path Initiative and CBER research programs on Feb. 17. The meeting will be held at the Bethesda, Md. Holiday Inn at 8:30 a.m. on both days. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.